Skip to main content
. Author manuscript; available in PMC: 2017 Dec 5.
Published in final edited form as: Nat Biomed Eng. 2017 Jun 5;1:0078. doi: 10.1038/s41551-017-0078

Table 3.

Summary of long-term efficacy after 8 weeks of treatment with GLP1-ELPopt

Treatment
Group		 Number of
Subjects		 Day 0 HbA1c
(%)		 Day 28 HbA1c
(%)		 Day 56 HbA1c
(%)		 Day 0 Weight
(g)		 Day 56 Weight
(g)		 56-Day Glucose
AUC, Normalized
ob/ob Mouse Model
GLP1-ELPopt 5 4.4 ± 0.2 5.0 ± 0.2 5.8 ± 0.2 32.2 ± 1.0 49.3 ± 1.1 0.67 ± 0.01
PBS Control 5 4.4 ± 0.1 5.7 ± 0.2 6.5 ± 0.2 31.5 ± 0.7 54.1 ± 0.8 1.00 ± 0.04
DIO Mouse Model
GLP1-ELPopt 5 NM NM 4.4 ± 0.1 23.1 ± 0.5 25.6 ± 0.9 0.74 ± 0.04
PBS Control 5 NM NM 4.9 ± 0.1 24.0 ± 0.5 32.6 ± 1.4 1.00 ± 0.02

Values reported are the mean and SEM.